Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.

Carpenter WR, Meyer AM, Wu Y, Qaqish B, Sanoff HK, Goldberg RM, Weiner BJ.

Med Care. 2012 Aug;50(8):737-48. doi: 10.1097/MLR.0b013e31824ebe13.

2.

Provider-based research networks may improve early access to innovative colon cancer treatment for African Americans treated in the community.

Penn DC, Chang Y, Meyer AM, DeFilippo Mack C, Sanoff HK, Stitzenberg KB, Carpenter WR.

Cancer. 2015 Jan 1;121(1):93-101. doi: 10.1002/cncr.29028. Epub 2014 Sep 10.

3.

Differential receipt of sentinel lymph node biopsy within practice-based research networks.

Meyer AM, Reeder-Hayes KE, Liu H, Wheeler SB, Penn D, Weiner BJ, Carpenter WR.

Med Care. 2013 Sep;51(9):812-8. doi: 10.1097/MLR.0b013e31829c8ca4.

4.

Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.

Tan HJ, Meyer AM, Kuo TM, Smith AB, Wheeler SB, Carpenter WR, Nielsen ME.

Cancer. 2015 Mar 15;121(6):836-43. doi: 10.1002/cncr.29144. Epub 2014 Nov 19.

PMID:
25410684
5.

The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation.

Carpenter WR, Reeder-Hayes K, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, Godley PA.

Med Care. 2011 Feb;49(2):172-9. doi: 10.1097/MLR.0b013e3182028ff2.

6.

Racial disparities in receipt and comparative effectiveness of oxaliplatin for stage III colon cancer in older adults.

Mack CD, Carpenter W, Meyer AM, Sanoff H, Stürmer T.

Cancer. 2012 Jun 1;118(11):2925-34. doi: 10.1002/cncr.26622. Epub 2011 Nov 9.

7.

Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.

Panchal JM, Lairson DR, Chan W, Du XL.

Clin Colorectal Cancer. 2013 Jun;12(2):113-21. doi: 10.1016/j.clcc.2012.09.007. Epub 2012 Nov 6.

PMID:
23137529
8.

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation.

Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P.

Health Technol Assess. 2006 Nov;10(41):iii-iv, xi-xiv, 1-185. Review.

9.

Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis.

Sanoff HK, Carpenter WR, Freburger J, Li L, Chen K, Zullig LL, Goldberg RM, Schymura MJ, Schrag D.

Cancer. 2012 Sep 1;118(17):4309-20. doi: 10.1002/cncr.27422. Epub 2012 Jan 31.

10.

Implementing community-based provider participation in research: an empirical study.

Teal R, Bergmire DM, Johnston M, Weiner BJ.

Implement Sci. 2012 May 8;7:41. doi: 10.1186/1748-5908-7-41.

11.

Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.

Kim JY, Kim YJ, Lee KW, Lee JS, Kim DW, Kang SB, Lee HS, Jang NY, Kim JS, Kim JH.

Jpn J Clin Oncol. 2013 Feb;43(2):132-8. doi: 10.1093/jjco/hys195. Epub 2012 Nov 29.

12.

Comparative effectiveness of different chemotherapeutic regimens on survival of people aged 66 and older with stage III colon cancer: a "real world" analysis using Surveillance, Epidemiology, and End Results-Medicare data.

Hsiao FY, Mullins CD, Onukwugha E, Pandya N, Hanna N.

J Am Geriatr Soc. 2011 Sep;59(9):1717-23. doi: 10.1111/j.1532-5415.2011.03501.x. Epub 2011 Aug 10.

PMID:
21831168
13.

Provider-based research networks demonstrate greater hospice use for minority patients with lung cancer.

Penn DC, Stitzenberg KB, Cobran EK, Godley PA.

J Oncol Pract. 2014 Jul;10(4):e182-90. doi: 10.1200/JOP.2013.001268. Epub 2014 Apr 29.

14.

Practice setting and physician influences on judgments of colon cancer treatment by community physicians.

McFall SL, Warnecke RB, Kaluzny AD, Ford L.

Health Serv Res. 1996 Apr;31(1):5-19.

15.

Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years.

Sanoff HK, Carpenter WR, Stürmer T, Goldberg RM, Martin CF, Fine JP, McCleary NJ, Meyerhardt JA, Niland J, Kahn KL, Schymura MJ, Schrag D.

J Clin Oncol. 2012 Jul 20;30(21):2624-34. doi: 10.1200/JCO.2011.41.1140. Epub 2012 Jun 4.

16.

Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy.

Mack CD, Glynn RJ, Brookhart MA, Carpenter WR, Meyer AM, Sandler RS, Stürmer T.

Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):810-8. doi: 10.1002/pds.3386. Epub 2013 Jan 7.

17.

Why providers participate in clinical trials: considering the National Cancer Institute's Community Clinical Oncology Program.

McAlearney AS, Song PH, Reiter KL.

Contemp Clin Trials. 2012 Nov;33(6):1143-9. doi: 10.1016/j.cct.2012.08.008. Epub 2012 Aug 19.

18.

A method for analyzing the business case for provider participation in the National Cancer Institute's Community Clinical Oncology Program and similar federally funded, provider-based research networks.

Reiter KL, Song PH, Minasian L, Good M, Weiner BJ, McAlearney AS.

Cancer. 2012 Sep 1;118(17):4253-61. doi: 10.1002/cncr.27375. Epub 2011 Dec 27.

19.

Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB.

J Clin Oncol. 2002 Oct 1;20(19):3999-4005.

PMID:
12351597
20.

Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer.

Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI.

Ann Intern Med. 2002 Mar 5;136(5):349-57.

PMID:
11874307
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk